U.S. FDA Extends Rev
U.S. FDA Extends Review for TLANDO™; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged
November 17, 2017 08:00 ET | Lipocine Inc.
SALT LAKE CITY, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has extended the...
Lipocine Announces F
Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017
November 08, 2017 08:00 ET | Lipocine Inc.
SALT LAKE CITY, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended September 30,...
FDA Advisory Committ
FDA Advisory Committee Scheduled to Review TLANDO™ on January 10, 2018
October 18, 2017 08:00 ET | Lipocine Inc.
SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has scheduled the...
Lipocine Announces M
Lipocine Announces Motions Decision by USPTO in Interference Against Clarus
September 21, 2017 08:00 ET | Lipocine, Inc.
SALT LAKE CITY , Sept. 21, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Patent Trial and Appeal Board (“PTAB”) of the United...
Lipocine Announces F
Lipocine Announces FDA Advisory Committee Meeting for TLANDO™
September 20, 2017 08:00 ET | Lipocine, Inc.
SALT LAKE CITY, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Urologic Drugs Advisory Committee...
Lipocine to Present
Lipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference
September 19, 2017 15:01 ET | Lipocine, Inc.
SALT LAKE CITY, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a...
Lipocine to Present
Lipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 05, 2017 08:00 ET | Lipocine, Inc.
SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a...
Lipocine Announces F
Lipocine Announces FDA Acknowledgement of TLANDO™ (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018
August 14, 2017 08:00 ET | Lipocine, Inc.
SALT LAKE CITY, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration (“FDA”) has...
Lipocine Resubmits N
Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism
August 09, 2017 08:00 ET | Lipocine, Inc.
SALT LAKE CITY, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the resubmission of a New Drug Application (“NDA”) for LPCN 1021,...
Lipocine Announces F
Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017
August 07, 2017 08:00 ET | Lipocine, Inc.
SALT LAKE CITY, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2017....